ADMA Biologics Sued for Securities Law Violations

DJS Law Group has announced the commencement of a class action lawsuit against ADMA Biologics, Inc. ("ADMA" or "the Company"). The lawsuit alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. The suit is filed against ADMA, a NASDAQ-listed entity trading under the ticker symbol ADMA.

The complaint asserts that ADMA Biologics issued false and misleading statements to investors regarding the company's business operations and future outlook. These alleged misrepresentations are said to have artificially inflated the company's stock price, leading to financial losses for investors when the truth emerged.

Investors who purchased ADMA Biologics stock within a specified period are encouraged by DJS Law Group to contact the firm to discuss their legal rights and potential participation in the class action. The lawsuit seeks to recover damages for shareholders who were harmed by the alleged misconduct.

The case will proceed through the legal system, and further details regarding its progression and potential outcomes are expected to be disclosed as the litigation unfolds. ADMA Biologics has not yet issued a public statement regarding the lawsuit.